given that they have partnered E and have a sliding scale on royalties @$1B their cut is most likely around 20/25% based on Worldwide revenues for just the Endo indication. value the company on after tax EPS of about $2.50 X 40X multiple we get a $100 stock just for Endo indication. I give it a 40x multiple because E for UF would be most likely filed and have a FDA padufa date. Royalties most likely move towards 30% when E for UF indication reaches the market and ramps toward another $1B in sales.
Just another thought long term - please give me guidance if I'm totally off base. A $1 Billion in sales/revenue and with a average industry P/S ratio of 7.5 and we could be looking at a PPS of $130ish correct?? How off-base is this logic? or math????
Too many variables for me to venture a guess. NBIX appears to be in strong hands waiting for later stage Endo and UF announcements, so I suspect its stock price will not be that affected by tax considerations.